Metabolic dysfunction-associated steatotic liver disease
Therapeutic area
Endocrinology
Rare disease
Yes
- Definition
- Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease or NAFLD) is a type of liver disease that is not caused by alcohol. It typically does not cause symptoms in the early stages, but it can cause health problems due to fat accumulation, inflammation, and scarring in the liver.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Metabolic dysfunction-associated steatotic liver disease
- Therapeutic area
- Endocrinology
- metabolic dysfunction-associated steatotic liver disease
- MASLD
- NAFLD
- NAFLD - nonalcoholic fatty liver disease
- fatty liver disease, nonalcoholic
- non-alcoholic fatty liver
- non-alcoholic fatty liver disease
- nonalcoholic fatty liver disease
- NAFLD1
- fatty liver disease, nonalcoholic, susceptibility to, 1
- Severity
- Mild
- Endocrinology
- Gastroenterology
- MONDO ID
- MONDO:0013209
- Parent condition
- MONDO:0004790
Related records
Broader conditions (8)
- Digestive system disorder
- Disease
- Disease by body system or component
- Endocrine system disorder
- Fatty liver disease
- Hepatobiliary disorder
- Human disease
- Liver disorder
Narrower conditions (2)
Trials (1,706)
- "CAP" Fetge Gras. Lifestyle Modification Program in Catalonia.
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
- "Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)
- "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
- 12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
- 2-Week Study In People With Nonalcoholic Fatty Liver Disease
- 2000 HIV Human Functional Genomics Partnership Program
- 24-h-ambulatory Blood Pressure Monitoring and Pulse Wave Analysis in NAFLD Patients
- 31P Magnetic Resonance Spectroscopy Fructose Study
- 6-week Safety and PD Study in Adults With NAFLD
- A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
- A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
- A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity
- A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
- A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
- A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD
- A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Approved drugs (1)
- Resmetirom
Drugs in development (118)
- Acarbose Phase 2
- Acetylcysteine Early phase 1
- Ademetionine Phase 3
- Aldafermin Phase 2
- ASP-9831 Phase 2
- Aspirin Phase 2
- Atorvastatin Phase 2
- Belapectin Phase 2
- Berberine Phase 2
- Berberine ursodeoxycholate Phase 1
- BMS-963272 Phase 1
- Carbocysteine Phase 2
- Cenicriviroc Phase 3
- Cholecalciferol Phase 3
- Cilofexor Phase 2
- Clesacostat Phase 2
- Clesacostat tromethamine Phase 1
- Cotadutide Phase 2
- Cysteamine bitartrate Phase 2
- Dabigatran etexilate Phase 1
Other linked drugs (1)
- Rifaximin